Cargando…
Can vitamin D(3) supplementation prevent bone loss in persons with MS? A placebo-controlled trial
Multiple sclerosis (MS) is a possible cause of secondary osteoporosis. In this phase II trial we assessed whether a weekly dose of 20,000 IU vitamin D(3) prevents bone loss in ambulatory persons with MS age 18–50 years. ClinicalTrials.gov ID NCT00785473. All patients managed at the University Hospit...
Autores principales: | Steffensen, Linn H., Jørgensen, Lone, Straume, Bjørn, Mellgren, Svein Ivar, Kampman, Margitta T. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer-Verlag
2011
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3165120/ https://www.ncbi.nlm.nih.gov/pubmed/21400196 http://dx.doi.org/10.1007/s00415-011-5980-6 |
Ejemplares similares
-
High dose vitamin D supplementation does not affect biochemical bone markers in multiple sclerosis – a randomized controlled trial
por: Holmøy, Trygve, et al.
Publicado: (2017) -
Segregation analysis in families with Charcot-Marie-Tooth disease allows reclassification of putative disease causing mutations
por: Østern, Rune, et al.
Publicado: (2014) -
Small- and Large-Fiber Neuropathy After 40 Years of Type 1 Diabetes: Associations with glycemic control and advanced protein glycation: the Oslo Study
por: Sveen, Kari Anne, et al.
Publicado: (2013) -
Effects of omega 3 supplementation in elderly patients with acute myocardial infarction: design of a prospective randomized placebo controlled study
por: Laake, Kristian, et al.
Publicado: (2014) -
Salmon Fillet Intake Led to Higher Serum Triacylglycerol in Obese Zucker Fa/Fa Rats But Not in Normolipidemic Long-Evans Rats
por: Vikøren, Linn Anja, et al.
Publicado: (2018)